www.nordion.com

First Quarter Fiscal 2013 Earnings Conference Call

March 6, 2013

2

Caution on Forward Looking Statements

This presentation contains forward-looking statements, within the meaning of applicable securities laws, including under applicable Canadian securities laws and the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. These statements can be identified by expressions of belief, expectation or intention, as well as those statements that are not historical fact. The words “may”, “will”, “could”, “should”, “would”, “outlook”, “believe”, “plan”, “anticipate”, “estimate”, “expect” and similar words and expressions are also intended to identify forward-looking statements. Forward-looking statements are necessarily based on estimates and assumptions made by us in light of our experience and our perception of historical trends, current conditions and expected future developments, as well as other factors that we believe are appropriate in the circumstances, but which are inherently subject to significant business, political, economic and competitive uncertainties and contingencies. Known and unknown factors could cause actual results to differ materially from those projected in the forward-looking statements. Accordingly, this presentation is subject to the disclaimer and qualified by the assumptions, qualifications and risk factors referred to in our 2012 Annual Information Form (AIF).

We caution readers not to place undue reliance on the Company’s forward-looking statements, as a number of factors could cause our actual results, performance or achievements to differ materially from any forward-looking statements. We do not assume any obligation to update or revise any forward-looking statements, whether written or oral, that may be made from time to time by us or on our behalf, except as required by applicable law.

3

Non GAAP Information

To supplement the financial measures prepared in accordance with generally accepted accounting principles (GAAP), the company uses non-GAAP financial measures such as adjusted net income and adjusted earnings per share. Non-GAAP financial measures exclude certain items, such as restructuring charges and recovery, change in fair value of embedded derivatives, AECL arbitration and legal fees, loss and gains on sales of investments, loss or gains on discontinued operations, and tax effects on adjusted items. Management uses non-GAAP financial measures internally for strategic decision making, forecasting future results and evaluating current performance. By disclosing non-GAAP financial measures, management intends to provide investors with a meaningful, consistent comparison of the company's core operating results and trends for the periods presented. Non-GAAP financial measures are not prepared in accordance with GAAP. Therefore, the information is not necessarily comparable to other companies and should be considered as a supplement to, not a substitute for, or superior to, the corresponding measures calculated in accordance with GAAP.

www.nordion.com

First Quarter Fiscal 2013 Earnings Conference Call

Steve West Chief Executive Officer

March 6, 2013

5

Q1 2013 Results

11.0 12.0

25.9 25.2

16.1 16.4

0

10

20

30

40

50

60

2012 2013 Q1 Q1

Targeted Therapies Sterilization Technologies Medical Isotopes

Segmented Revenue (US$ millions)

Segmented Earnings* (US$ millions)

* Excludes corporate segmented loss

3.1 1.4

7.7

6.9

4.5

3.5

0

2

4

6

8

10

12

14

16

18

2012 2013

6 20

13 O

UTL

OO

K

Targeted Therapies: TheraSphere®

Build the Targeted Therapies business.

• $12.0 million in revenue up 9% over Q1/12

• Added 4 new sites in the U.S. and 6 in EMEA

• Launched new global TheraSphere® website

• Initiated STOP-HCC clinical trial sites in Canada and Europe

• Annual growth in the mid-teen percent range

• Growth in the second half of fiscal 2013 will be stronger than in the first half of the year

STRATEGY

Q1 R

ESULTS

7 20

13 O

UTL

OO

K

STRATEGY

Specialty Isotopes: Sterilization Technologies

Maintain cash generation and selectively invest in

growth.

• $16.4 million revenue up 2% compared to Q1/12

• Cobalt revenue of $15.4 million decreased 2% over Q1/12

• $1.1 million in Sterilization – Other revenue due to refurbishment work performed on existing production irradiators

• Maintain market-leading position and continue generating high margins

• Strengthen relationships with current customers and enter into new and emerging markets

• Selectively grow gamma sterilization sales over the long-term

Q1 R

ESULTS

8 20

13 O

UTL

OO

K

STRATEGY

Q1 R

ESULTS

Specialty Isotopes: Medical Isotopes

Optimize the value of the business.

• $25.2 million revenues, decreased 2.6% compared with Q1 fiscal 2012

• Reactor isotopes revenue was $20.4 million, a decrease of $0.5 million or 3% over Q1/12

• Contract manufacturing revenues were up 6% over Q1/12

• Maintain medical isotopes sales by working closely with existing customers to bring additional value

• Explore strategic opportunities for cyclotron based medical isotopes

• Assess opportunities to obtain reliable and long-term supply of medical isotopes

www.nordion.com

First Quarter Fiscal 2013 Earnings Conference Call

Peter Dans Chief Financial Officer

March 6, 2013

10

Q1 2013 Financial Performance

Targeted Therapies

Sterilization Technologies

Medical Isotopes

CONSOLIDATED RESULTS • Q1 revenue of $53.7 million; up 1% over

Q1/12

• GAAP net loss of $0.3 million

• Adjusted net income of $4.1 million down from $7.1 million over Q1/12

• Non-GAAP EPS decreased to $0.07 compared with $0.11 non-GAAP EPS in Q1/12

• Gross margin percentages were 52% in Q1/13

*EXCLUDES CORPORATE SEGEMENTED LOSS

Q1 Segmented Revenue (US$ millions)

Q1 Segmented Earnings* (US$ millions)

3.1 1.4

7.7 6.9

4.5

3.5

0

5

10

15

20

2012 2013

11.0 12.0

25.9 25.2

16.1 16.4

0 10 20 30 40 50 60

2012 2013

11

Business Segments

OVERVIEW & FINANCIAL OUTLOOK – Targeted Therapies

• Revenue grew 9% over Q1/12; segment earnings were down 54% due to higher spend in support of sales and marketing, and Phase III clinical trials

• TheraSphere® revenue is expected to grow in the mid-teen percentage range in fiscal 2013

• Phase III clinical trial spending is expected to be in the range of $6-8 million in fiscal 2013

• Significant additional investments in fiscal 2013 to support TheraSphere® long-term global growth

12

Business Segments

OVERVIEW & FINANCIAL OUTLOOK – Specialty Isotopes: Sterilization Technologies

• Revenue increased by 2%

• Segment earnings were down 21% due to lower Co-60 sales volumes

• In fiscal 2013, Sterilization Technologies revenue is expected to be approximately the same as in fiscal 2012; Co-60 revenue is expected to be similar to fiscal 2012

• Fiscal 2013 quarterly profile of Co-60 revenue is expected to be similar to fiscal 2012

13

Business Segments

OVERVIEW & FINANCIAL OUTLOOK – Specialty Isotope: Medical Isotopes

• Revenues of $25.2 million and earnings of $6.9 million in Q1 for Reactor, Cyclotron isotopes and contract manufacturing

• Reactor isotopes revenue was $20.4 million, a decrease of 3% compared to Q1/12

• Total Medical Isotopes revenue is expected to decline in the mid-teen range in fiscal 2013, compared to the original annual forecast of 20%

www.nordion.com

First Quarter Fiscal 2013 Earnings Conference Call

March 6, 2013